Mectizan Donation Program | Local power. Global Change.
MERCK A program at The Task Force for Global Health
Switch to French site

MDP News & Resources

Looking for specific news & resource articles?
Enter a search phrase, select a category or topic, and click the green search button below.

Report

Reaching the Criteria to Stop Onchocerciasis Mass Drug Administration: Ethiopia, Nigeria, and Uganda Pave the Way

Part of the Act to End NTDS | East technical brief series June 2021.

To eliminate human onchocerciasis transmission of the filarial parasite Onchocerca volvulus (OV), endemic countries undertake a multi-step processi to: 1.

Reaching the criteria to stop OV MDA (9.30 MB)

Annual Highlights

2020 Mectizan Donation Program Annual Highlights (English) | Faits saillants de l’année 2020 du PDM (édition française)

MDP 2020: Investing for Impact. This publication summarizes the accomplishments of the Mectizan Donation Program and its partners in 2020.

PDM 2020: Investir pour l’impact.

Mectizan-Donation-Program-Annual-Highlights-2020-English (3.81 MB)

MDP Newsletter

Mectizan Program Notes – Spring 2021

Welcome to a new season in the campaign to eliminate river blindness and elephantiasis. Although the events of last year put many obstacles in our path, below you will find news of progress made thanks to the determination of all partners to continue the fight to #StampOutOncho and #eliminateLF from the planet.

Mectizan Expert Committee Statement on Mectizan Use During the COVID-19 Pandemic

A Mectizan Expert Committee (MEC) Statement on the use of Mectizan® during the COVID-19 pandemic: The MEC reminds country partners that Mectizan is donated only for the elimination of onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis).

Declaración del Comité de Expertos de Mectizan (MEC) sobre el uso de Mectizan®

Declaración del Comité de Expertos de Mectizan (MEC) sobre el uso de Mectizan®: El MEC recuerda a los países socios que Mectizan es donado únicamente para la eliminación de la oncocercosis (ceguera de los ríos) y la filariasis linfática (elefantiasis)

La pandemia de COVID-19 ha despertado el interés de los medios de comunicación y un incremento de las publicaciones sobre la acción de la ivermectina en la replicación viral del SARS-Cov-2.

Déclaration du Comité d’Experts de Mectizan (CEM) sur l’utilisation du Mectizan®

Déclaration du Comité d’Experts de Mectizan (CEM) sur l’utilisation du Mectizan® : Le Comité rappelle à nos pays partenaires que le Mectizan® est exclusivement donné pour l’élimination de l’onchocercose (cécité des rivières) et la filariose lymphatique (éléphantiasis).

Declaração do Comitê de Especialistas do Mectizan (CEM) sobre o uso de Mectizan®

Declaração do Comitê de Especialistas do Mectizan (CEM) sobre o uso de Mectizan®: O Comitê lembra aos países parceiros que o Mectizan® é dado exclusivamente para a eliminação da oncocercose (cegueira do rio) e filariose linfática (elefantíase).

News

Lymphatic Filariasis Eliminated in Malawi

28 October 2020

The World Health Organization (WHO) announced in this week’s WHO Weekly Epidemiological Record that Malawi has been validated to have eliminated lymphatic filariasis as a public health problem.

MDP/Merck Grant Application For Supplementary Funding for COVID-19 Mitigation

This is the Mectizan Donation Program and Merck & Co., Inc. grant application to assist non-governmental organization (NGO) partners with resuming mass drug administration by supporting implementation of COVID-19 mitigation strategies.

MDP Grant Application For Supplementary Funding for COVID-19 Mitigation rev 5.17.21 (88.38 KB)

Annual Highlights

2019 Mectizan Donation Program Annual Highlights (English)

These are the accomplishments of the Mectizan Donation Program and its partners in 2019.

MDP Annual Highlights 2019 (English) (8.27 MB)

Annual Highlights

2019 Mectizan Donation Program Annual Highlights (French)

These are the accomplishments of the Mectizan Donation Program and its partners in 2019.

MDP Annual Highlights 2019 (French) (9.08 MB)

MDP Publication: Building country capacity to sustain NTD programs and progress: A call to action

This research article, co-authored by MDP’s Yao Sodahlon and Joni Lawrence, Merck’s Rachel Taylor, The Task Force for Global Health’s CEO, Dave Ross, and many NTD program managers, is focused on the need for building country capacity by increasing country ownership and domestic spending for NTD programs.

Sodahlon et al., 2020 (453.99 KB)

Documents

PAHO Recommendation regarding the use of Ivermectin as a treatment for COVID-19

A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications on observational clinical studies reported the apparent utility of ivermectin to treat patients with COVID-19 needing mechanical ventilation; neither of these studies were peer-reviewed nor formally published and one of them was later retracted.

PAHO Recommendation Regarding the Use of Ivermectin as a Treatment for COVID-19 (381.44 KB)

Videos

Video of microfilariae in the anterior chamber of the eye

This is footage[1] of microfilariae was captured in a 59-year-old man’s anterior chamber of the eye. The man lives in an onchocerciasis-endemic area in eastern Ghana.

Appearance of Mf in the anterior chamber (25.87 MB)

Videos

MDP’s Commitment to WHO’s Road Map 2021 – 2030

The Mectizan Donation Program is committed to working towards WHO’s NTD Road Map 2030 targets and the path towards eliminating river blindness and lymphatic filariasis.

Videos

Stamp Out Oncho – A Community Drug Distributor’s Dedication On Distribution

This short film covers the dedication of a community drug distributor on working towards eliminating onchocerciasis (river blindness) in Cameroon, Africa.

Scientific Publication

Publication: Low transmission of Wuchereria bancrofti in cross-border districts of Côte d’Ivoire: A great step towards lymphatic filariasis elimination in West Africa

This research article focuses on the results of four rounds of mass drug administration (MDA) for cross-border districts of Côte d’Ivoire where lymphatic filariasis (LF) is endemic.

Yokoly et al., 2020 (1.05 MB)

Scientific Publication

Publication: Post-Treatment Surveillance for Lymphatic Filariasis in Plateau and Nasarawa States, Nigeria: Results of Transmission Assessment Surveys

In order to confirm that transmission recrudescence or importation does not occur for lymphatic filariasis (LF) after mass drug administration (MDA), the WHO recommends post-treatment surveillance.

Eigege et al., 2020 (321.96 KB)